Roche Invirase/Abbott Norvir combination study shows 99.6% reduction in HIV viral load at six weeks.
Executive Summary
ROCHE INVIRASE/ABBOTT NORVIR COMBO THERAPY SIX-WEEK DATA show a reduction of 99.6% in viral load from early results presented July 11 at the International Conference on AIDS in Vancouver. The study, funded by both companies, is the first to test two protease inhibitors in combination and without nucleoside analogs.